CTLA4-Ig Immunoadhesin Variants for Stronger B7-2 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CTLA4-Ig immunoadhesins, such as abatacept, have suboptimal affinity for B7 ligands, particularly B7-2, leading to inadequate efficacy in treating autoimmune diseases and disorders beyond rheumatoid arthritis.
Innovation Solution
Development of novel CTLA4-Ig immunoadhesins with specific amino acid modifications, such as A29H, T51N, L61E, and K93Q, to enhance binding to B7-1 and B7-2, thereby improving T-cell inhibitory activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native CTLA4-Ig immunoadhesins (e.g., abatacept) are used, then the structure is simple and manufacturing is easier, but the affinity for B7 ligands (particularly B7-2) is suboptimal, leading to inadequate efficacy
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid residues in the CTLA4 binding domain (e.g., positions 29, 51, 61, 93) to alter the biochemical parameters of B7 ligand binding. These point mutations change the affinity characteristics without fundamentally redesigning the entire immunoadhesin structure, thereby improving efficacy while maintaining relative structural simplicity
Solution Approach 2:
The patent creates composite molecular structures by combining the CTLA4 extracellular domain with the IgG Fc region, and further composite variants by introducing specific amino acid substitutions. This composite approach allows optimization of the binding interface while preserving the overall immunoadhesin architecture and Fc-mediated functions
2Force
If amino acid modifications are introduced to enhance B7 binding affinity, then the binding strength to B7-1 and B7-2 is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent modifies specific biochemical parameters (amino acid sequences at defined positions) to enhance binding affinity. These are precise, localized changes rather than global structural modifications, making them relatively straightforward to implement through recombinant DNA technology and standard protein expression protocols
Solution Approach 2:
The patent applies local quality by introducing amino acid modifications only at specific positions within the CTLA4 binding domain that are predicted to or demonstrated to affect B7 ligand interaction. The rest of the molecule remains unchanged, preserving ease of manufacturing while locally optimizing binding properties
Data Source
AI summary
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.